Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2Stomach Neoplasms 1Sarcoma, Clear Cell 1Rectal Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms by Site 1Multiple Myeloma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Carboplatin 4Pemetrexed 3pembrolizumab 2patritumab 2osimertinib 2Sunitinib 2Standard of Care 2Paclitaxel 2Irinotecan 2Cisplatin 2Ascorbic Acid 2valrubicin 1pralsetinib 1palbociclib 1napabucasin 1linifanib 1genexol-PM 1dostarlimab 1alectinib 1Watchful Waiting 1Sorafenib 1Ramucirumab 1Patient Reported Outcome Measures 1Mitomycin 1KRN-330 1Interleukin-2 1Indocyanine Green 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gemcitabine 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms by Site × dostarlimab × Clear all
NCT05980416 2025-11-14

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Elevation Oncology

Phase 1 Terminated
88 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡